Yaribeygi, H.; Hemmati, M.A.; Nasimi, F.; Maleki, M.; Jamialahmadi, T.; Reiner, I.; Reiner, Ž.; Sahebkar, A.
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats. J. Clin. Med. 2023, 12, 3815.
https://doi.org/10.3390/jcm12113815
AMA Style
Yaribeygi H, Hemmati MA, Nasimi F, Maleki M, Jamialahmadi T, Reiner I, Reiner Ž, Sahebkar A.
Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats. Journal of Clinical Medicine. 2023; 12(11):3815.
https://doi.org/10.3390/jcm12113815
Chicago/Turabian Style
Yaribeygi, Habib, Mohammad Amin Hemmati, Fatemeh Nasimi, Mina Maleki, Tannaz Jamialahmadi, Ivan Reiner, Željko Reiner, and Amirhossein Sahebkar.
2023. "Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats" Journal of Clinical Medicine 12, no. 11: 3815.
https://doi.org/10.3390/jcm12113815
APA Style
Yaribeygi, H., Hemmati, M. A., Nasimi, F., Maleki, M., Jamialahmadi, T., Reiner, I., Reiner, Ž., & Sahebkar, A.
(2023). Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats. Journal of Clinical Medicine, 12(11), 3815.
https://doi.org/10.3390/jcm12113815
